ScripRhythm Pharmaceuticals plans to build out its sales force to target endocrinologists as it looks ahead to filing for US Food and Drug Administration approval of setmelanotide in acquired hypothalamic
ScripUS initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Novartis To Pay Argo $185m Up Fron
In VivoComing off the back of a challenging 2021 and 2022, many industry analysts cautiously forecast a bigger 2023, more deals, mergers and IPOs. While this has not happened, bar a few delicious morsels suc